MedTrace Logo

Evaluation of Adhesion and Dermal Tolerability of EMSAM

NCT00531596 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2007-09-19

No results posted yet for this study

Summary

Examine adhesive and dermal tolerability of EMSAm 6mg/24hr and 12mg/24hr in healthy elderly and non-elderly subjects.

Conditions

  • Healthy

Interventions

DRUG

EMSAM (Selegiline Transdermal System) 6mg/24Hr

EMSAM 6mg/24HR

DRUG

EMSAM (Selegiline Transdermal System) 9mg/24Hr

EMSAM 9mg/24Hr

DRUG

EMSAM (Selegiline Transdermal System) 12mg/24hr

EMSAM 12mg/24Hr

Sponsors & Collaborators

  • Somerset Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Melissa Goodhead · Somerset Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-04-30
Completion
2007-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00531596 on ClinicalTrials.gov